Pelvic Inflammatory Disease

The current emphasis on evidence-based medicine has poorly served our approach to pelvic inflammatory disease. On paper, the goal of determining the best therapeutic strategy by prospective randomized double-blind studies is laudable, but it makes the assumption that patients with similar risk factors can be grouped into large study groups for such endeavors. It is increasingly apparent that this has not been the case.